Premium
Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly
Author(s) -
Ferrara Felicetto,
Mirto Salvatore
Publication year - 1996
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1996.00398.x
Subject(s) - medicine , proportional hazards model , chemotherapy , hazard ratio , clinical significance , multivariate analysis , oncology , disease , lactic dehydrogenase , survival analysis , gastroenterology , confidence interval , biology , biochemistry , enzyme
72 patients aged over 60 suffering from acute myelogenous leukaemia (AML) and treated with aggressive chemotherapy were analysed with the aim of finding factors of prognostic relevance. With regard to complete remission achievement, the only variable of statistical significance found was the karyotype at diagnosis. As far as overall survival, in multivariate analysis performed by Cox hazard regression model, unfavourable karyotype and serum lactic dehydrogenase (LDH) >400 IU/l were significantly related to an adverse clinical outcome. Finally, serum LDH was the only parameter to significantly influence disease‐free survival. We conclude that serum LDH is a main prognostic factor in AML of the elderly and a potentially useful tool for identifying subsets of patients who may obtain a substantial advantage from aggressive chemotherapy.